IL-1β reactivity and the development of severe fatigue after military deployment: a longitudinal study

Journal of Neuroinflammation

Cobi J Heijnen³  Elbert Geuze¹  Eric Vermetten¹  Mirjam Maas³  Karima Amarouchi³  Annemieke Kavelaars²  Mirjam van Zuiden⁴ 

[1] Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands;Integrative Immunology and Behavior Program, University of Illinois Urbana Champaign, 61801, Urbana, IL, USA;Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), University Medical Center Utrecht, KC.03.068.0, P.O. Box 85090, 3508 AB, Utrecht, the Netherlands;Department of Psychiatry, Academic Medical Center, University of Amsterdam, Meibergdreef 5, 1105 AZ, Amsterdam, the Netherlands

关键词: Interleukin-8;    LPS;    Military;    Reactivity;    Receptor;    Interleukin-1;    Cytokine;    Inflammation;    Stress;    Fatigue;   

Others  :  1160278
DOI  :  10.1186/1742-2094-9-205

 received in 2012-03-30, accepted in 2012-08-09,  发布年份 2012

【 摘 要 】

Background

It has been suggested that pro-inflammatory cytokine signaling to the brain may contribute to severe fatigue. We propose that not only the level of circulating cytokines, but also increased reactivity of target cells to cytokines contributes to the effect of cytokines on behavior. Based on this concept, we assessed the reactivity of peripheral blood cells to IL-1β in vitro as a novel approach to investigate whether severe fatigue is associated with increased pro-inflammatory signaling.

Methods

We included 504 soldiers before deployment to a combat-zone. We examined fatigue severity and the response to in vitro stimulation with IL-1β prior to deployment (T0), and 1 (T1) and 6 months (T2) after deployment. IL-8 production was used as read-out. As a control we determined LPS-induced IL-8 production. The presence of severe fatigue was assessed with the Checklist Individual Strength (CIS-20R). Differences in dose–response and the longitudinal course of IL-1β and LPS-induced IL-8 production and fatigue severity were investigated using repeated measures ANOVA.

Results

At T2, the group who had developed severe fatigue (n = 65) had significantly higher IL-1β-induced IL-8 production than the non-fatigued group (n = 439). This group difference was not present at T0, but developed over time. Longitudinal analysis revealed that in the non-fatigued group, IL-1β-induced IL-8 production decreased over time, while IL-1β-induced IL-8 production in the fatigued group had not decreased. To determine whether the observed group difference was specific for IL-1β reactivity, we also analyzed longitudinal LPS-induced IL-8 production. We did not observe a group difference in LPS-induced IL-8 production.

Conclusions

Collectively, our findings indicate that severe fatigue is associated with a higher reactivity to IL-1β. We propose that assessment of the reactivity of the immune system to IL-1β may represent a promising novel method to investigate the association between behavioral abnormalities and pro-inflammatory cytokine signaling.

【 授权许可】

   
2012 van Zuiden et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]De Vries M, Soetekouw PMMB, Van Der Meer JWM, Bleijenberg G: Fatigue in Cambodia veterans. QJM 2000, 93:283-289.
• [2]Kang HK, Natelson BH, Mahan CM, Lee KY, Murphy FM: Post-Traumatic Stress Disorder and Chronic Fatigue Syndrome-like Illness among Gulf War Veterans: A Population-based Survey of 30,000 Veterans. Am J Epidemiol 2003, 157:141-148.
• [3]Lyall M, Peakman M, Wessely S: A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res 2003, 55:79-90.
• [4]Silverman MN, Heim CM, Nater UM, Marques AH, Sternberg EM: Neuroendocrine and immune contributors to fatigue. PM R 2010, 2:338-346.
• [5]Bower JE: Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun 2007, 21:863-871.
• [6]Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR: Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008, 26:971-982.
• [7]Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G: Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8:287-291.
• [8]Zhang Q, Zhou XD, Denny T, Ottenweller JE, Lange G, LaManca JJ, Lavietes MH, Pollet C, Gause WC, Natelson BH: Changes in immune parameters seen in Gulf War veterans but not in civilians with chronic fatigue syndrome. Clin Diagn Lab Immunol 1999, 6:6-13.
• [9]Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA: Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis 1994, Suppl 1:S147-S153.
• [10]Meyer T, Stanske B, Kochen MM, Cordes A, Yuksel I, Wachter R, Luers C, Scherer M, Binder L, Pieske B, Herrmann-Lingen C: Elevated serum levels of interleukin-10 and tumor necrosis factor alpha [corrected] are both associated with vital exhaustion in patients with cardiovascular risk factors. Psychosomatics 2010, 51:248-256.
• [11]Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG: Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009, 7:96. BioMed Central Full Text
• [12]Meyers CA, Albitar M, Estey E: Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793.
• [13]White AT, Light AR, Hughen RW, Bateman L, Martins TB, Hill HR, Light KC: Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. Psychophysiology 2010, 47:615-624.
• [14]Heijnen CJ, Kavelaars A: The importance of being receptive. J Neuroimmunol 1999, 100:197-202.
• [15]Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
• [16]Maier SF: Bi-directional immune-brain communication: Implications for understanding stress, pain, and cognition. Brain Behav Immun 2003, 17:69-85.
• [17]Omdal R, Gunnarsson R: The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis - a pilot study. Rheumatol Int 2005, 25:481-484.
• [18]Parnet P, Kelley KW, Bluthe RM, Dantzer R: Expression and regulation of interleukin-1 receptors in the brain. Role in cytokines-induced sickness behavior. J Neuroimmunol 2002, 125:5-14.
• [19]van Zuiden M, Heijnen CJ, Maas M, Amarouchi K, Vermetten E, Geuze E, Kavelaars A: Glucocorticoid sensitivity of leukocytes predicts PTSD, depressive and fatigue symptoms after military deployment: a prospective study. Psychoneuroendocrinology 2012 Apr 11. Epub ahead of print
• [20]van Zuiden M, Heijnen CJ, van de Schoot R, Amarouchi K, Maas M, Vermetten E, Geuze E, Kavelaars A: Cytokine production by leukocytes of military personnel with depressive symptoms after deployment to a combat-zone: a prospective, longitudinal study. PLoS One 2011, 6:e29142.
• [21]van Zuiden M, Geuze E, Willemen HL, Vermetten E, Maas M, Amarouchi K, Kavelaars A, Heijnen CJ: Glucocorticoid receptor pathway components predict Posttraumatic Stress Disorder symptom development: a prospective study. Biol Psychiatry 2012, 71:309-316.
• [22]van Zuiden M, Geuze E, Willemen HL, Vermetten E, Maas M, Heijnen CJ, Kavelaars A: Pre-existing high glucocorticoid receptor number predicting development of posttraumatic stress symptoms after military deployment. Am J Psychiatry 2011, 168:89-96.
• [23]van Zuiden M, Geuze E, Maas M, Vermetten E, Heijnen CJ, Kavelaars A: Deployment-related severe fatigue with depressive symptoms is associated with increased glucocorticoid binding to peripheral blood mononuclear cells. Brain Behav Immun 2009, 23:1132-1139.
• [24]van Zuiden M, Kavelaars A, Rademaker AR, Vermetten E, Heijnen CJ, Geuze E: A prospective study on personality and the cortisol awakening response to predict posttraumatic stress symptoms in response to military deployment. J Psychiatr Res 2011, 45:713-719.
• [25]Vercoulen JHMM, Alberts M, Bleijenberg G: The Checklist Individual Strength. Gedragstherapie 1999, 32:131-136.
• [26]Bellehumeur C, Blanchet J, Fontaine JY, Bourcier N, Akoum A: Interleukin 1 regulates its own receptors in human endometrial cells via distinct mechanisms. Hum Reprod 2009, 24:2193-2204.
• [27]Kasza A, Wyrzykowska P, Horwacik I, Tymoszuk P, Mizgalska D, Palmer K, Rokita H, Sharrocks AD, Jura J: Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12A expression. BMC Mol Biol 2010, 11:14. BioMed Central Full Text
• [28]Griffin WS, Liu L, Li Y, Mrak RE, Barger SW: Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation 2006, 3:5. BioMed Central Full Text
• [29]Ralay Ranaivo H, Zunich SM, Choi N, Hodge JN, Wainwright MS: Mild stretch-induced injury increases susceptibility to interleukin-1beta-induced release of matrix metalloproteinase-9 from astrocytes. J Neurotrauma 2011, 28:1757-1766.
• [30]de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT: Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003, 10:133-139.
• [31]Kline RB: Principles and practice of structural equation modeling. 2nd edition. New York, NY: Guilford Press; 2005.
• [32]Hansel A, Hong S, Camara RJ, von Kanel R: Inflammation as a psychophysiological biomarker in chronic psychosocial stress. Neurosci Biobehav Rev 2010, 35:115-121.
• [33]Miller GE, Rohleder N, Cole SW: Chronic interpersonal stress predicts activation of pro- and anti-inflammatory signaling pathways 6 months later. Psychosom Med 2009, 71:57-62.
• [34]Miller GE, Chen E, Sze J, Marin T, Arevalo JM, Doll R, Ma R, Cole SW: A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol Psychiatry 2008, 64:266-272.
• [35]Roebuck KA: Regulation of interleukin-8 gene expression. J Interferon Cytokine Res 1999, 19:429-438.
• [36]Auron PE: The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev 1998, 9:221-237.
• [37]Abramson SB, Amin A: Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002, 41:972-980.
• [38]Churchill L, Taishi P, Wang M, Brandt J, Cearley C, Rehman A, Krueger JM: Brain distribution of cytokine mRNA induced by systemic administration of interleukin-1beta or tumor necrosis factor alpha. Brain Res 2006, 1120:64-73.